Valneva's Lyme Vaccine Conundrum: Efficacy Meets Statistical Hurdle

Valneva's Lyme disease vaccine candidate showed 73% efficacy but missed a key statistical endpoint, causing a 43% stock drop and attracting U.S. law firm investigations.

The French biotech firm Valneva finds itself navigating a complex paradox. Its Lyme disease vaccine candidate, VLA15, developed with Pfizer, demonstrated a solid ability to prevent the illness but failed a key statistical test required for regulatory success. This outcome has triggered a sharp sell-off in the company's shares and attracted the attention of U.S. law firms.

Investors reacted swiftly to the uncertainty, sending Valneva's stock tumbling. Over the past 30 days, the share price has collapsed by more than 43 percent, currently trading at 2.70 euros. The decline was particularly severe on the day the Phase 3 trial data was released in late March, when U.S.-listed shares plummeted over 37 percent.

The core of the issue lies in the VALOR trial results. While the vaccine showed a protective efficacy of 73.2 percent against confirmed Lyme disease cases, it did not meet its primary statistical endpoint. The lower bound of the confidence interval was only 15.8 percent, falling short of the pre-specified success threshold of 20 percent. The company and its partner attribute this not to a lack of medical relevance, but to a lower-than-expected number of infections occurring during the study period.

This clinical and regulatory ambiguity has now escalated into a legal challenge. Following an initial probe by Pomerantz LLP, a second U.S. law firm, Bronstein, Gewirtz & Grossman, has launched an investigation. The firms are examining whether Valneva's management made potentially misleading statements regarding the trial's expectations prior to the data release. Such investigations in the U.S. often lead to costly class-action lawsuits that can drain significant resources.

Despite the setback, Valneva and Pfizer are pushing forward with their regulatory strategy. They aim to convince the U.S. Food and Drug Administration (FDA) with the vaccine's demonstrated efficacy, which they report as being in the range of 73 to 75 percent compared to placebo. Chief Executive Thomas Lingelbach has framed the next steps as a matter of negotiation with regulators, with the goal of submitting a marketing application in the second half of 2026.

The company's financial resilience will be critical to sustaining this path. As of the turn of the year, Valneva held cash reserves of approximately 110 million euros. The firm has also managed to reduce its operational cash burn by 21 percent recently. Upcoming quarterly results on May 7 will provide a clearer picture of whether this liquidity is sufficient to fund both the ongoing development and potential legal costs.

Elsewhere in its portfolio, Valneva's Chikungunya vaccine, IXCHIQ, presents a mixed picture. In Brazil, a pilot campaign with partner Instituto Butantan is underway, having already vaccinated over 12,000 people. The vaccine received marketing authorization there a year ago, marking the first such approval in an endemic country. However, the U.S. market remains closed for now, as Valneva voluntarily withdrew its application there in January.

Institutional investors, including Frazier Life Sciences, continue to hold their positions, with major funds and hedge funds collectively owning around eleven percent of the stock. The company's next major public appearance is scheduled for April 15, 2026, at the Van Lanschot Kempen Life Sciences Conference, where management will present the adjusted regulatory strategy for the Lyme program and provide an update on the Chikungunya vaccine commercialization.